Information Provided By:
Fly News Breaks for August 30, 2017
Aug 30, 2017 | 07:15 EDT
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
News For ABCO;UNH From the Last 2 Days
Jul 17, 2019 | 13:27 EDT
Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $3.45... Honeywell (HON), consensus $2.08... Philip Morris (PM), consensus $1.32... Union Pacific (UNP), consensus $2.14... Danaher (DHR), consensus $1.16... Morgan Stanley (MS), consensus $1.14... Blackstone (BX), consensus 50c... BB&T Corp (BBT), consensus $1.07... SunTrust Banks (STI), consensus $1.45... Nucor (NUE), consensus $1.32... Genuine Parts (GPC), consensus $1.65... Ally Financial (ALLY), consensus 88c.
Jul 16, 2019 | 16:18 EDT
UnitedHealth (UNH) recently issued a coverage decision stating that theta burst TMS has been deemed "unproven and not medically necessary," which will make obtaining reimbursement from the insurer more difficult in the future for theta burst providers, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This would specifically impact MagVentures, which has been mentioned frequently as a key competitor to monitor for Neuronetics (STIM), adds the analyst. The analyst says that with no changes to the reimbursement pathway for Neuronetics in the coverage update, he views the news as incrementally positive for the company as it competes in the theta-burst stimulation category for major depressive disorder patients. O'Brien reiterates an Overweight rating on Neuronetics and continues to view the name as his favorite small cap idea.
Jul 15, 2019 | 11:06 EDT
Cleveland Research analyst Steve Willoughby said earlier today that his recent work indicates UnitedHealth continues to gain share across both the UHC and OptumRx businesses. Feedback on the upcoming Medicare Advantage Annual Election Period points to UnitedHealth likely being best positioned to lead the market in membership growth, Willoughby wrote in a research note. The analyst's Q2, 2019 and 2020 estimates are ahead of consensus and keeps a Buy rating on UnitedHealth shares.